NCT04872582

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: A Single Center, Single Arm, Phase II Clinical Study.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: XIANG YANQUN · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy.

Detailed description

To evaluate the efficacy and safety of sintilimab combined with bevacizumab in the treatment of metastatic nasopharyngeal carcinoma (NPC) after platinum-based chemotherapy failure. The primary end point is objective response rate (ORR), the secondary end points are overall survival (OS), progression-free survival (PFS), duration of response (DOR), adverse effects and quality of life.

Conditions

• Metastatic Nasopharyngeal Carcinoma
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab	combined

Timeline

• Start date: 2021-07-29
• Primary completion: 2023-01-04
• Completion: 2024-10-01
• First posted: 2021-05-04
• Last updated: 2023-02-23

Locations

1 site across 1 country: China